darolutamide-话题@MedSci

#darolutamide#

8篇内容 | 922人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2189167, encodeId=a20c218916e5e, content=<a href='/topic/show?id=9360202054' target=_blank style='color:#2F92EE;'>#ADT疗法#</a> <a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a> <a href='/topic/show?id=7b6b111506cc' target=_blank style='color:#2F92EE;'>#转移性激素敏感性前列腺癌#</a>, objectTitle=Eur Urol Oncol：激素敏感性前列腺癌男性患者口服darolutamide单药与雄激素剥夺疗法的 2 期随机开放标签研究（EORTC-GUCG 1532）比较, objectType=article, longId=814499, objectId=ad5281449915, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240224/1708743945237_1935437.jpg, objectUrl=/article/show_article.do?id=ad5281449915, replyNumber=0, likeNumber=26, createdTime=2024-02-24, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=ad5281449915, moduleTitle=Eur Urol Oncol：激素敏感性前列腺癌男性患者口服darolutamide单药与雄激素剥夺疗法的 2 期随机开放标签研究（EORTC-GUCG 1532）比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ad5281449915)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1423381, encodeId=2c861423381ad, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, objectTitle=NEJM：Darolutamide联合雄激素剥夺疗法-多西他赛治疗转移性激素敏感前列腺癌, objectType=article, longId=299122, objectId=f136299122b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f136299122b1, replyNumber=0, likeNumber=37, createdTime=2022-02-20, rootId=0, userName=yangcx0916, userId=6ab13776446, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f136299122b1, moduleTitle=NEJM：Darolutamide联合雄激素剥夺疗法-多西他赛治疗转移性激素敏感前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f136299122b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423380, encodeId=6d4c142338086, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, objectTitle=Eur J Cancer：Darolutamide可显著改善非转移性去势抵抗性前列腺癌患者的健康相关生活质量, objectType=article, longId=215209, objectId=93d5215209e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93d5215209e6, replyNumber=0, likeNumber=25, createdTime=2021-08-04, rootId=0, userName=yangcx0916, userId=6ab13776446, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93d5215209e6, moduleTitle=Eur J Cancer：Darolutamide可显著改善非转移性去势抵抗性前列腺癌患者的健康相关生活质量, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93d5215209e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423379, encodeId=c64714233e99c, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, objectTitle=NEJM：Nubeqa（darolutamide）显著延长非转移性前列腺癌患者的寿命！, objectType=article, longId=200507, objectId=259720050e88, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=259720050e88, replyNumber=0, likeNumber=39, createdTime=2020-09-12, rootId=0, userName=yangcx0916, userId=6ab13776446, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=259720050e88, moduleTitle=NEJM：Nubeqa（darolutamide）显著延长非转移性前列腺癌患者的寿命！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=259720050e88)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423378, encodeId=3da314233e81f, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, objectTitle=2019ESMO-Asia：Darolutamide延缓非转移性前列腺癌患者的疾病进展和化疗时间, objectType=article, longId=183719, objectId=f1bc183e1902, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f1bc183e1902, replyNumber=0, likeNumber=37, createdTime=2019-11-30, rootId=0, userName=yangcx0916, userId=6ab13776446, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f1bc183e1902, moduleTitle=2019ESMO-Asia：Darolutamide延缓非转移性前列腺癌患者的疾病进展和化疗时间, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f1bc183e1902)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423377, encodeId=2e4414233e74d, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, objectTitle=Bayer/Orion的非甾体雄激素受体拮抗剂darolutamide治疗前列腺癌获得FDA优先审查, objectType=article, longId=165296, objectId=373b1652964b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=373b1652964b, replyNumber=0, likeNumber=33, createdTime=2019-05-03, rootId=0, userName=yangcx0916, userId=6ab13776446, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=373b1652964b, moduleTitle=Bayer/Orion的非甾体雄激素受体拮抗剂darolutamide治疗前列腺癌获得FDA优先审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=373b1652964b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423376, encodeId=7d4f14233e6d6, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, objectTitle=多拉米胺Darolutamide在欧盟申请上市，用于治疗非转移性去势抵抗性前列腺癌, objectType=article, longId=162125, objectId=bf0c162125cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf0c162125cc, replyNumber=0, likeNumber=32, createdTime=2019-03-13, rootId=0, userName=yangcx0916, userId=6ab13776446, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf0c162125cc, moduleTitle=多拉米胺Darolutamide在欧盟申请上市，用于治疗非转移性去势抵抗性前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf0c162125cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423375, encodeId=dd5414233e52c, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, objectTitle=Darolutamide治疗非转移性去势抵抗性前列腺癌已向FDA滚动提交完成, objectType=article, longId=161512, objectId=f0b416151215, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f0b416151215, replyNumber=0, likeNumber=32, createdTime=2019-03-03, rootId=0, userName=yangcx0916, userId=6ab13776446, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f0b416151215, moduleTitle=Darolutamide治疗非转移性去势抵抗性前列腺癌已向FDA滚动提交完成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0b416151215)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1423374, encodeId=9b4314233e41c, content=<a href='/topic/show?id=48e55e0461' target=_blank style='color:#2F92EE;'>#darolutamide#</a>, objectTitle=darolutamide联合雄激素剥夺疗法在非转移性去势抵抗性前列腺癌中显著延长了PFS, objectType=article, longId=160341, objectId=61af160341ee, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61af160341ee, replyNumber=0, likeNumber=28, createdTime=2019-02-19, rootId=0, userName=yangcx0916, userId=6ab13776446, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61af160341ee, moduleTitle=darolutamide联合雄激素剥夺疗法在非转移性去势抵抗性前列腺癌中显著延长了PFS, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61af160341ee)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

darolutamide

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#ADT疗法# #darolutamide# #转移性激素敏感性前列腺癌#

Eur Urol Oncol：激素敏感性前列腺癌男性患者口服darolutamide单药与雄激素剥夺疗法的 2 期随机开放标签研究（EORTC-GUCG 1532）比较

2024-02-24发表于上海

yangcx0916 (审核中...)

前往app查看评论内容

#darolutamide#

NEJM：Darolutamide联合雄激素剥夺疗法-多西他赛治疗转移性激素敏感前列腺癌

2022-02-20

yangcx0916 (审核中...)

前往app查看评论内容

#darolutamide#

Eur J Cancer：Darolutamide可显著改善非转移性去势抵抗性前列腺癌患者的健康相关生活质量

2021-08-04

yangcx0916 (审核中...)

前往app查看评论内容

#darolutamide#

NEJM：Nubeqa（darolutamide）显著延长非转移性前列腺癌患者的寿命！

2020-09-12

yangcx0916 (审核中...)

前往app查看评论内容

#darolutamide#

2019ESMO-Asia：Darolutamide延缓非转移性前列腺癌患者的疾病进展和化疗时间

2019-11-30

yangcx0916 (审核中...)

前往app查看评论内容

#darolutamide#

Bayer/Orion的非甾体雄激素受体拮抗剂darolutamide治疗前列腺癌获得FDA优先审查

2019-05-03

yangcx0916 (审核中...)

前往app查看评论内容

#darolutamide#

多拉米胺Darolutamide在欧盟申请上市，用于治疗非转移性去势抵抗性前列腺癌

2019-03-13

yangcx0916 (审核中...)

前往app查看评论内容

#darolutamide#

Darolutamide治疗非转移性去势抵抗性前列腺癌已向FDA滚动提交完成

2019-03-03

yangcx0916 (审核中...)

前往app查看评论内容

#darolutamide#

darolutamide联合雄激素剥夺疗法在非转移性去势抵抗性前列腺癌中显著延长了PFS

2019-02-19

科室
- - 订阅+
  - 更多科室
工具
服务